Annexon is a C1q “stop-the-start” complement platform nearing a 2026–2027 inflection: GBS filings are underway and GA Phase 3 is the defining binary catalyst.
Overview
Annexon (ANNX) is a clinical-stage biopharmaceutical company developing therapies for complement-mediated neuroinflammatory diseases by targeting **C1q**, the initiating protein of the classical complement pathway. The company’s differentiation is upstream inhibition intended to protect synapses, neurons, and tissue from aberrant immune-mediated damage—contrasting with complement competitors that target downstream proteins like C3 or C5. Annexon’s pipeline is organized into autoimmune, ophthalmic, and neurodegenerative/broader autoimmune segments: (1) **tanruprubart (ANX005)**, an IV monoclonal antibody in registrational stage for **Guillain-Barré Syndrome (GBS)**; (2) **vonaprument (ANX007)**, an intravitreal Fab for **Geographic Atrophy (GA)**; and (3) **ANX1502**, a first-in-kind **oral C1s inhibitor** being evaluated in **Cold Agglutinin Disease (CAD)**. The company has no commercial products and thus no product revenue; it has funded operations primarily through equity financing, including an **$86.25M offering in late 2025**, with notable institutional ownership (e.g., FMR ~7.1%, BlackRock ~6.1%). 2026 is positioned as an inflection year: Annexon submitted an **EMA MAA (Jan 2026)** for tanruprubart in GBS and expects an **FDA BLA filing in 2026**, while also anticipating **topline Phase 3 ARCHER II results for vonaprument in 2H 2026**. With **$188.7M** cash and short-term investments (late 2025) and runway into **late Q1 2027**, the company is attempting to bridge from late-stage R&D to potential commercial launch planning and execution.